Howie Rosen is an independent consultant and serves on the board of directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), ALCOBRA, LTD (NASDAQ: ADHD), where he has served as Chairman since 2014, ALDEA Pharmaceuticals, Inc., Entrega, Inc., Kala Pharmaceuticals, Inc., where he has served as Chairman since 2014 and PaxVax, Inc., where he has served as Chairman since 2011. From 2004 to 2008, he was Vice President, Commercial Strategy at Gilead Sciences, Inc. where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead’s overall portfolio and business planning.
Prior to joining Gilead, Mr. Rosen was President of ALZA Corporation where he was responsible for all aspects of managing ALZA as an independent 1000-person operating company within the Johnson & Johnson Family of Companies. Previously at ALZA as Vice President, Product Development, he was responsible for product development activities, portfolio management and corporate and new product planning. Over his 10 years at ALZA, Mr. Rosen also had responsibilities for mergers and acquisitions, R&D planning, and technology ventures. Prior to joining ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., was Director, Corporate Development at GenPharm International, Inc. and was a consultant in the San Francisco office of McKinsey & Co. Mr. Rosen was a member of the Stanford University Advisory Council on Interdisciplinary Biosciences from 2003 to 2011 and the Stanford School of Engineering Advisory Council from 2004 to 2007. Mr. Rosen is a member of the Biomedical Engineering Advisory Board at City College of New York and the BOD of the MIT Club of Northern California. Previously he was a member of the BODs of CNS Therapeutics, Inc., CoTherix, Inc., NTF Therapeutics, Inc., Pearl Therapeutics, Inc., where he served as interim President and CEO from June 2010 to March 2011, and Pharsight Corporation.
Mr. Rosen is a Lecturer in the Department of Chemical Engineering at Stanford and a Lecturer in Management at the Stanford Graduate School of Business. He is also a member of the National Academy of Engineering (NAE), where he is Chair of the Bioengineering Section, and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He is co-inventor on 7 US patents. Mr. Rosen received an MBA from the Stanford Graduate School of Business, where he graduated first in his class as the Henry Ford II Scholar. Mr. Rosen has an MS in Chemical Engineering from MIT and he graduated with distinction from Stanford University with a BS in Chemical Engineering.